Bolt Biotherapeutics, Inc.
$5.15
▼
-4.88%
2026-04-21 05:45:00
www.boltbio.com
NCM: BOLT
Explore Bolt Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.09 M
Current Price
$5.15
52W High / Low
$9.25 / $3.91
Stock P/E
—
Book Value
$13.8
Dividend Yield
—
ROCE
-71.68%
ROE
-79.75%
Face Value
—
EPS
$-17.85
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
23
Beta
0.86
Debt / Equity
86.62
Current Ratio
3.59
Quick Ratio
3.59
Forward P/E
-0.2
Price / Sales
1.23
Enterprise Value
$4.89 M
EV / EBITDA
-0.15
EV / Revenue
0.64
Rating
Buy
Target Price
$29
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Neumora Therapeutics, Inc. | $2.19 | — | $391.39 M | — | -152.06% | -1.21% | $3.65 / $0.61 | $0.6 |
| 2. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
| 3. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 4. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 5. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 6. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 7. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.5 M | 2.17 M | 1.8 M | 1.22 M | 0 M | — |
| Operating Profit | -5.61 M | -7.7 M | -9.21 M | -12.12 M | -15.67 M | — |
| Net Profit | -6.63 M | -7.14 M | -8.56 M | -11.04 M | -15.94 M | — |
| EPS in Rs | -3.45 | -3.72 | -4.46 | -5.75 | -8.29 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.7 M | 7.69 M | 7.88 M | 5.73 M |
| Operating Profit | -34.63 M | -68.24 M | -76.2 M | -90.32 M |
| Net Profit | -33.38 M | -63.12 M | -69.2 M | -88.1 M |
| EPS in Rs | -17.37 | -32.85 | -36.01 | -45.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 56.75 M | 99.63 M | 159.78 M | 227.81 M |
| Total Liabilities | 30.24 M | 42.43 M | 47.04 M | 56.3 M |
| Equity | 26.5 M | 57.2 M | 112.74 M | 171.51 M |
| Current Assets | 30.26 M | 50.81 M | 105.71 M | 172.75 M |
| Current Liabilities | 8.44 M | 15.86 M | 20.46 M | 23.12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -39.85 M | -61.29 M | -69.53 M | -76.5 M |
| Investing CF | 44.3 M | 57.58 M | 71.04 M | 57.86 M |
| Financing CF | 0.02 M | 0.11 M | 0.25 M | 0.5 M |
| Free CF | -39.92 M | -61.33 M | -69.73 M | -78.46 M |
| Capex | -0.07 M | -0.04 M | -0.21 M | -1.95 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -2.36% | 37.48% | — | — |
| Earnings Growth % | 8.79% | 21.45% | — | — |
| Profit Margin % | -820.78% | -878.58% | -1537.76% | — |
| Operating Margin % | -887.33% | -967.45% | -1576.56% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -864.17% | -943.91% | -1547.48% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-09 | 1:0.05 |